Cargando…
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
INTRODUCTION: Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce. METHOD: This prospective, age- and sex-matched, single-center cohort s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746434/ https://www.ncbi.nlm.nih.gov/pubmed/35976687 http://dx.doi.org/10.1080/21645515.2022.2104058 |
_version_ | 1784849358900953088 |
---|---|
author | Limpawittayakul, Piyarat Sungkasubun, Prakongboon Chaiwiriyawong, Worawit Supavavej, Archara Weerasubpong, Bowon Siripaibun, Jomtana Phanthunane, Chumut Lamlertthon, Wisut Ungtrakul, Teerapat Tawinprai, Kriangkrai Tantiyavarong, Walaipan Samdaengpan, Chayanee |
author_facet | Limpawittayakul, Piyarat Sungkasubun, Prakongboon Chaiwiriyawong, Worawit Supavavej, Archara Weerasubpong, Bowon Siripaibun, Jomtana Phanthunane, Chumut Lamlertthon, Wisut Ungtrakul, Teerapat Tawinprai, Kriangkrai Tantiyavarong, Walaipan Samdaengpan, Chayanee |
author_sort | Limpawittayakul, Piyarat |
collection | PubMed |
description | INTRODUCTION: Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce. METHOD: This prospective, age- and sex-matched, single-center cohort study included 61 cancer patients and 122 healthy control participants. Seropositivity was defined as anti-S IgG titer >0.8 units/ml. Primary end point was seroconversion rate of immunoglobulin (Ig)G antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein (anti-S IgG) in cancer patients vs. healthy control participants following the second dose of COVID-19 vaccine ChAdOx1 nCoV-19 (AZD1222). RESULTS: After the second-dose vaccination, there was no difference in seropositivity rate between groups (57 [93.44%] patients with cancer vs. 121 [99.18%] control participants; geometric mean ratio [GMR]: 0.39; 95%CI: 0.01–10.46; p-value = 0.571). In contrast, after the first-dose vaccination, the seropositivity rate was significantly lower in the cancer patients than in the control participants (50/61 [81.97%] vs. 121/122 [99.18%]; GMR: 0.07; 95%CI: 0.01–0.71; p = 0.025). The median anti-S IgG titer after the first-and second dose vaccination were not significantly different between groups. Female sex was significantly associated with a higher anti-S IgG titer. 5FU- and taxane-based chemotherapy regimens were associated with a lower IgG titer. Side effects of vaccination were tolerable. CONCLUSIONS: The anti-S IgG seropositivity rate after completing the second vaccine dose did not differ between the cancer patients and control participants. However, the anti-S IgG seropositivity rate after the first-dose vaccination was lower in cancer patients. |
format | Online Article Text |
id | pubmed-9746434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-97464342022-12-14 Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital Limpawittayakul, Piyarat Sungkasubun, Prakongboon Chaiwiriyawong, Worawit Supavavej, Archara Weerasubpong, Bowon Siripaibun, Jomtana Phanthunane, Chumut Lamlertthon, Wisut Ungtrakul, Teerapat Tawinprai, Kriangkrai Tantiyavarong, Walaipan Samdaengpan, Chayanee Hum Vaccin Immunother Coronavirus – Research Article INTRODUCTION: Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce. METHOD: This prospective, age- and sex-matched, single-center cohort study included 61 cancer patients and 122 healthy control participants. Seropositivity was defined as anti-S IgG titer >0.8 units/ml. Primary end point was seroconversion rate of immunoglobulin (Ig)G antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein (anti-S IgG) in cancer patients vs. healthy control participants following the second dose of COVID-19 vaccine ChAdOx1 nCoV-19 (AZD1222). RESULTS: After the second-dose vaccination, there was no difference in seropositivity rate between groups (57 [93.44%] patients with cancer vs. 121 [99.18%] control participants; geometric mean ratio [GMR]: 0.39; 95%CI: 0.01–10.46; p-value = 0.571). In contrast, after the first-dose vaccination, the seropositivity rate was significantly lower in the cancer patients than in the control participants (50/61 [81.97%] vs. 121/122 [99.18%]; GMR: 0.07; 95%CI: 0.01–0.71; p = 0.025). The median anti-S IgG titer after the first-and second dose vaccination were not significantly different between groups. Female sex was significantly associated with a higher anti-S IgG titer. 5FU- and taxane-based chemotherapy regimens were associated with a lower IgG titer. Side effects of vaccination were tolerable. CONCLUSIONS: The anti-S IgG seropositivity rate after completing the second vaccine dose did not differ between the cancer patients and control participants. However, the anti-S IgG seropositivity rate after the first-dose vaccination was lower in cancer patients. Taylor & Francis 2022-08-17 /pmc/articles/PMC9746434/ /pubmed/35976687 http://dx.doi.org/10.1080/21645515.2022.2104058 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Coronavirus – Research Article Limpawittayakul, Piyarat Sungkasubun, Prakongboon Chaiwiriyawong, Worawit Supavavej, Archara Weerasubpong, Bowon Siripaibun, Jomtana Phanthunane, Chumut Lamlertthon, Wisut Ungtrakul, Teerapat Tawinprai, Kriangkrai Tantiyavarong, Walaipan Samdaengpan, Chayanee Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital |
title | Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital |
title_full | Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital |
title_fullStr | Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital |
title_full_unstemmed | Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital |
title_short | Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital |
title_sort | immunogenicity evaluation of chadox1 ncov-19 (azd1222) vaccine in solid cancer patients in chulabhorn hospital |
topic | Coronavirus – Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746434/ https://www.ncbi.nlm.nih.gov/pubmed/35976687 http://dx.doi.org/10.1080/21645515.2022.2104058 |
work_keys_str_mv | AT limpawittayakulpiyarat immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT sungkasubunprakongboon immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT chaiwiriyawongworawit immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT supavavejarchara immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT weerasubpongbowon immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT siripaibunjomtana immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT phanthunanechumut immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT lamlertthonwisut immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT ungtrakulteerapat immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT tawinpraikriangkrai immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT tantiyavarongwalaipan immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital AT samdaengpanchayanee immunogenicityevaluationofchadox1ncov19azd1222vaccineinsolidcancerpatientsinchulabhornhospital |